Related Experiment Video
Updated: Jun 10, 2026
06:46
Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
Cognitive intervention in Alzheimer disease.
Verena Buschert1, Arun L W Bokde, Harald Hampel
1Dementia Research Section and Memory Clinic, Alzheimer Memorial Center, Department of Psychiatry, Ludwig-Maximilian University, Nussbaumstrasse 7, D-80366 Munich, Germany. verena.buschert@med.uni-muenchen.de
Nature Reviews. Neurology
|August 19, 2010
Summary
Cognitive interventions show promise for preventing and treating Alzheimer disease (AD), potentially offering greater symptom relief when combined with traditional medications. Further research, including neuroimaging, is recommended to explore its disease-modifying effects.
Area of Science:
- Gerontology and Neurodegenerative Diseases
- Cognitive Neuroscience
- Non-pharmacological Interventions
Background:
- Alzheimer disease (AD) is a prevalent condition in the elderly, with current antidementia drugs offering limited symptomatic relief.
- Non-invasive cognitive interventions are being explored for AD prevention and treatment.
- Combining pharmacological and non-pharmacological approaches may enhance symptom management in AD.
Purpose of the Study:
- To review the application of cognitive intervention in healthy aging and Alzheimer disease (AD) populations.
- To summarize evidence supporting the effectiveness of cognitive interventions for AD.
- To discuss the potential of cognitive interventions for disease modification in AD.
Main Methods:
- Review of existing literature on cognitive interventions in aging and AD.
- Analysis of emerging findings on the therapeutic benefits of cognitive interventions.
- Exploration of neuroimaging techniques (fMRI, structural MRI) to understand intervention effects on the brain.
Main Results:
- Cognitive interventions may induce beneficial biological changes in the brain.
- Evidence suggests cognitive interventions are effective in the healthy elderly and AD patients.
- Neuroimaging studies investigating cognitive intervention effects on the brain are emerging but underexplored.
Conclusions:
- Cognitive interventions represent a promising non-pharmacological approach for Alzheimer disease (AD) management.
- Combined therapies (pharmacological and cognitive) may offer superior clinical symptom relief.
- Future research should focus on neuroimaging to elucidate the disease-modifying potential of cognitive interventions in AD.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...